Related Experiment Video
Updated: Feb 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Pharmacokinetics and Dosimetry of [68Ga]Ga-PSMA-11 in Chinese Participants with Progressive Metastatic
Wei Fan1, Yonghong Li2, Hongcheng Shi2
1Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Introduction:
[68Ga]Ga-prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) imaging has demonstrated clinical value for individuals with prostate cancer (PC). In this phase 2 study, we measured the pharmacokinetics and dosimetry of [68Ga]Ga-PSMA-11 in Chinese participants.
Methods:
Adult Chinese participants with progressive metastatic castration-resistant PC (mCRPC) received a single intravenous [68Ga]Ga-PSMA-11 dose of approximately 150 MBq. Blood samples were collected at 5, 15, 30, 45, 85, 175, and 245 min post injection for pharmacokinetics assessments. Whole-body PET scans and low/ultra-low-dose CT scans were acquired at 30, 60, 120, and 255 min post injection for dosimetry assessments.
Results:
Pharmacokinetics and dosimetry assessments were completed in seven participants who received a [68Ga]Ga-PSMA-11 dose (range: 108.3-236.7 MBq). In the blood, the geometric mean effective terminal half-life was 1.34 h (geometric coefficient of variation [geo-CV], 182%); geometric mean clearance was 9.80 L/h (geo-CV, 106%). The highest absorbed doses were seen in the kidneys, urinary bladder walls, and lacrimal glands. In the study population, the geometric mean (geo-CV) effective dose of [68Ga]Ga-PSMA-11 was 4.2 mSv (32.9%).
Conclusions:
The pharmacokinetic and dosimetry profiles of [68Ga]Ga-PSMA-11, assessed using a validated method in participants with progressive mCRPC, make it very suitable with proves its suitability.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Treatment Resistant Cancers
Phase Diagrams
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Phase Transitions
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

